Inactive Instrument

News Nemus Bioscience Inc OTC Bulletin Board

Equities

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	Apr. 11	CI
Skye Bioscience Uplists to The Nasdaq Global Market	Apr. 10	AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	Apr. 03	PU
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating	Mar. 14	MT
Skye Bioscience, Inc. announced that it has received $40 million in funding	Mar. 12	CI
Skye Bioscience Announces $40 Million Private Placement Equity Financing	Mar. 11	NE
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	Mar. 10	CI
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	Mar. 04	AQ
Skye Bioscience Announces Board Changes	Mar. 04	CI
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	AQ
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	Feb. 11	CI
Skye Bioscience to Present at Oppenheimer Investor Conference	Feb. 07	NE
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	Jan. 29	NE
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	Jan. 28	CI
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	Jan. 09	NE
Skye Bioscience Responds to OTC Markets Promotional Policy	Dec. 11	AQ
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11	CI
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nemus Bioscience Inc OTC Bulletin Board

Equities

Summary

Filters